CNS Pharmaceuticals Announces Virtual Investor KOL Connect Segment
Segment featuring leading Neuro-Oncologist and Glioblastoma Key Opinion Leader, Professor Michael Weller Access the segment ...
CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
HOUSTON, TX / ACCESSWIRE / November 1, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)("CNS" or the "Company"), a ...
Biomednewsbreaks - CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Highlights Berubicin's Potential In Glioblastoma Treatment During KOL Connect Event
CNS Pharmaceuticals (NASDAQ: CNSP) , focused on innovative cancer therapies for brain and central nervous system cancers, recently participated in ...
Investing4d
CNS Pharmaceuticals granted Nasdaq compliance extension
HOUSTON - CNS Pharmaceuticals, Inc. (NASDAQ:CNSP), a biopharmaceutical company focused on developing novel treatments for brain and central nervous system cancers, announced it has received an ...
CNS Pharmaceuticals granted exception by Nasdaq to regain compliance
CNS Pharmaceuticals (CNSP) announced that on October 30, 2024, it received notice from The Nasdaq Hearings Panel that the Company has been ...
Biomednewsbreaks CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Granted Nasdaq Extension For Compliance
CNS Pharmaceuticals (NASDAQ: CNSP) announced that it received an exception from the nasdaq Hearings Panel, granting the company until March 11, 2025, to meet the minimum bid price requirement under ...
Morningstar5d
CNS Pharmaceuticals Granted Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...